Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Friday.

Other equities analysts have also issued reports about the company. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a report on Tuesday, September 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Supernus Pharmaceuticals in a report on Saturday, September 27th. Finally, Piper Sandler boosted their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a “neutral” rating in a research report on Friday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.50.

Supernus Pharmaceuticals Trading Up 0.8%

NASDAQ:SUPN opened at $48.35 on Friday. The firm has a market capitalization of $2.71 billion, a PE ratio of 42.04 and a beta of 0.78. The stock has a 50 day moving average of $43.52 and a 200-day moving average of $36.14. Supernus Pharmaceuticals has a 52 week low of $29.16 and a 52 week high of $49.66.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 140,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares of the company’s stock, valued at approximately $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total value of $524,092.20. Following the completion of the transaction, the chief financial officer directly owned 1,246 shares in the company, valued at $55,434.54. This represents a 90.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 302,841 shares of company stock valued at $13,361,449 in the last three months. Insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in Supernus Pharmaceuticals by 107.3% during the 3rd quarter. GAMMA Investing LLC now owns 5,932 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 3,071 shares during the period. Praxis Investment Management Inc. acquired a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at $243,000. Corient Private Wealth LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $248,000. Osaic Holdings Inc. raised its stake in Supernus Pharmaceuticals by 211.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,328 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Supernus Pharmaceuticals by 9.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 21,245 shares of the specialty pharmaceutical company’s stock valued at $670,000 after purchasing an additional 1,893 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.